Several analysts have recently updated their ratings and price targets for Anthem (NYSE: ANTM):

  • 10/4/2017 – Anthem had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $202.00 price target on the stock.
  • 9/21/2017 – Anthem had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $160.00 price target on the stock.
  • 9/20/2017 – Anthem was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $207.00 price target on the stock. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. Its strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The company has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017.”
  • 9/20/2017 – Anthem had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
  • 9/19/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. Its strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The company has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, the company's interest expenses increase due to mounting level of debt that continues to weigh on margins. Also softness in public exchange business remains a major headwind.”
  • 9/15/2017 – Anthem was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/14/2017 – Anthem had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
  • 9/14/2017 – Anthem was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $212.00 price target on the stock. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The company has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017.”
  • 9/12/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The company has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, weak public exchange business remains a major area of concern. Also, rising level of debt continues to weigh on margins.”
  • 9/6/2017 – Anthem was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $221.00 price target on the stock. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The stock has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017.”
  • 9/6/2017 – Anthem was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 9/5/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The stock has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, the company’s rising level of debt results in increasing interest expenses that continues to drain the margin. Also its weak public exchange business bothers.”
  • 8/30/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. In last 30 days, the Zacks Consensus Estimate for 2017 and 2018 has been revised upward. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, the company’s high-debt level poses financial risk. Rising interest expenses may hurt margins.  Also, the company’s weak public exchange business continues to bother.”
  • 8/24/2017 – Anthem was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $219.00 price target on the stock. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestures and ACO arrangements further pave the way for long-term growth. The company’s strong capital position backs effective capital deployment. The company’s frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. In last 30 days, the Zacks Consensus Estimate for 2017 and 2018 has revised upward. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, the company’s high-debt level poses financial risk. Rising interest expenses may hurt margins.  Also, the company’s weak public exchange business continues to bother.”
  • 8/23/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. Tthe company’s diverse product portfoliohas  helped in improving underwriting results. Anthem’s strategic acquisitions, divestures and ACO arrangements further paves the way for long-term growth. The company’s strong capital position backs effective capital deployment. Frequent share buybacks and regular dividend payments primarily aim at enhancing shareholders’ value. During the most recently reported quarter its earnings per share not only surpassed the Zacks Consensus Estimate but also rose year over year on higher revenues. However rising interest expenses associated to its high-debt levels and weak public exchange business bothers.”
  • 8/20/2017 – Anthem had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $204.00 price target on the stock.
  • 8/17/2017 – Anthem had its price target raised by analysts at Morgan Stanley from $196.00 to $201.00. They now have an “equal weight” rating on the stock.

Anthem, Inc. (NYSE:ANTM) traded up 0.47% during mid-day trading on Wednesday, reaching $194.13. 391,182 shares of the company were exchanged. The company’s 50 day moving average price is $190.53 and its 200-day moving average price is $183.68. The stock has a market capitalization of $50.98 billion, a price-to-earnings ratio of 18.36 and a beta of 0.71. Anthem, Inc. has a 12-month low of $114.85 and a 12-month high of $198.98.

Anthem (NYSE:ANTM) last issued its quarterly earnings data on Wednesday, July 26th. The company reported $3.37 earnings per share for the quarter, topping the consensus estimate of $3.23 by $0.14. The business had revenue of $22.20 billion during the quarter, compared to analysts’ expectations of $22.25 billion. Anthem had a net margin of 3.24% and a return on equity of 12.93%. The business’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.33 EPS. On average, equities research analysts forecast that Anthem, Inc. will post $11.84 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Monday, September 25th. Shareholders of record on Friday, September 8th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.45%. The ex-dividend date of this dividend was Thursday, September 7th. This is a positive change from Anthem’s previous quarterly dividend of $0.65. Anthem’s dividend payout ratio is presently 26.52%.

In other news, EVP Thomas C. Zielinski sold 9,127 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $191.25, for a total transaction of $1,745,538.75. Following the sale, the executive vice president now directly owns 26,571 shares of the company’s stock, valued at approximately $5,081,703.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Julie A. Hill sold 524 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $190.80, for a total value of $99,979.20. Following the sale, the director now directly owns 36,924 shares in the company, valued at $7,045,099.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,776 shares of company stock worth $6,007,143. Company insiders own 0.36% of the company’s stock.

Anthem, Inc is a health benefits company. The Company operates through three segments: Commercial and Specialty Business, Government Business and Other. It offers a spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products.

Receive News & Ratings for Anthem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthem Inc and related companies with MarketBeat.com's FREE daily email newsletter.